Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 4Unknown 2Recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2

Conditions

Multiple Myeloma 87Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Recurrence 16Burkitt Lymphoma 13Neoplasms 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Biphenotypic, Acute 7Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 6Lung Neoplasms 6Immunoglobulin Light-chain Amyloidosis 6Neoplasms, Plasma Cell 5Hodgkin Disease 5Smoldering Multiple Myeloma 4Leukemia 4Carcinoma, Non-Small-Cell Lung 4Waldenstrom Macroglobulinemia 3Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Neoplasm Metastasis 3Nausea 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Brain Neoplasms 3Renal Insufficiency 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Lymphoma, B-Cell 2Leukemia, Plasma Cell 2

Interventions

fludarabine 2Lenalidomide 2Dexamethasone 2Cyclophosphamide 2talquetamab 1isatuximab 1idecabtagene vicleucel 1fludarabine phosphate 1Whole-Body Irradiation 1Sirolimus 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Hematopoietic Stem Cell Transplantation 1Budesonide 1Bortezomib 1Allopurinol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Leukemia, Plasma Cell × Dexamethasone × Clear all
NCT05870917 2026-03-02

A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Recruiting
20 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

NCT06517017 2025-11-28

UltraFrailMM

University of Utah

Phase 2 Recruiting
40 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡